Patients with rare cancers often face difficulties obtaining insurance coverage for targeted therapies that lack specific Food and Drug Administration (FDA) approval for their condition. The issue was highlighted by the case of Mason Henderson, a 21-year-old from Texas who died in May after a months-long effort to secure the drug Lynparza for a rare brain tumor. While Henderson’s physicians justified the off-label use based on genetic mutations in his tumor, his insurance and pharmacy benefit manager (PBM) initially refused to pay, citing a lack of approved guidelines for his specific cancer.
Medical experts state that while genomic testing can identify mutations that may respond to specific drugs, insurance reimbursement protocols frequently require large-scale clinical trials. For rare cancers, which the National Cancer Institute defines as affecting fewer than 40,000 people per year, such trials are often not feasible. According to Olivier Elemento of Weill Cornell Medicine, insurance coverage routinely trails behind the scientific support provided by genomic testing.
In Henderson's case, his neuro-oncologists at Baylor College of Medicine and NYU Langone Health prescribed Lynparza, a drug originally approved for ovarian cancer, after chemotherapy failed to slow a diffuse hemispheric glioma. The pharmacy benefit manager, Liviniti, refused the request on Jan. 30, stating the drug was not approved for the diagnosis. The out-of-pocket cost for the medication was reported at approximately $8,700 per month. Henderson eventually received the drug through a manufacturer assistance program after his mother’s social media campaign, but he died roughly two months later.
The scale of the problem is significant given that there are only about 25,000 primary brain cancer diagnoses in the U.S. annually, compared to hundreds of thousands for breast or lung cancers. Because rare cancers represent smaller markets, pharmaceutical companies may be less inclined to fund the expensive clinical trials required for FDA labels. This creates a cycle where insurers deny coverage based on a lack of FDA-approved labels, despite genomic evidence suggesting a treatment might be effective.
What happens next depends on the evolution of "tissue agnostic" drug approvals and the integration of genomic data into standard medical guidelines. The FDA has approved nine tissue-agnostic drugs as of 2022, which target specific mutations regardless of where the cancer originated. Research programs like the TAPUR study, which has recruited over 3,000 patients since 2016, continue to provide off-label treatments to gather data. If these studies lead to updated expert guidelines, it may create more reliable pathways for insurance reimbursement for rare cancer patients in the future.